131 incretin-based therapies CANADIAN JOURNAL OF DIABETES. 2008;32(2): 131-139. There is a growing interest in developing therapeutic strategies for type 2 diabetes based on the actions of the hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insu-linotropic polypeptide (GIP).
Incretin-Based Therapies Viewpoints on the way to consensus MICHAEL.A.NAUCK, MD 1 TINA VILSBØLL, MD 2 BAPTIST GALLWITZ, MD 3 ALAN GARBER, MD 4 STEN MADSBAD, MD
How do incretins affect blood sugar levels? After you eat, your intestines release incretins such as GLP-1 into the bloodstream. GLP-1 affects blood sugar by: •Increasing insulin produced by your pancreas •Decreasing glucagon release (Glucagon is a hormone that controls the release of ...
Advanced Studies inMedicine ■ S1065 ABSTRACT Incretin hormones, which stimulate insulin secre tion, are produced by the gastrointestinal tract in
Hypoglycemics, Incretin Enhancers/Mimetics Review 06/22/2009 Copyright © 2007 - 2009 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America.
Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients
S12 CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 76 • SUPPLEMENT 5 DECEMBER 2009 ABSTRACT Q Nutrient intake stimulates the secretion of the gastrointestinal incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which exert ...
Rev. 06/22/11) NEBRASKA MEDICAID PROGRAM REQUEST FOR PRIOR AUTHORIZATION OF PAYMENT INCRETIN MIMETIC AGENTS (NOTE: All incretin mimetic agents approved subsequent to this bulletin shall be subject to these criteria.)
Pg.2 Latest Insights into Incretin-based Therapies and the Importance of Cardiovascular Risk Factor Control: An Update Report from EASD, Stockholm, September 2010 This program is intended for an international audience of healthcare professionals and is not intended for US and UK ...
J MCP JOURNAL OF MANAGED CARE PHARMACY ® Incretin Mimetics: Promising New Therapeutic Options in the Treatment of Type 2 Diabetes Jeremy M. Gleeson, MD, FACP, FACE David M. Berenbeim, MD, MBA, FACP Robert J. Gilkin, Jr., RPh, MBA Supplement September 2005 Vol. 11, No. 7 Continuing Education Program